about
Insight to drug delivery aspects for colorectal cancerPharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerationsOncogene withdrawal engages the immune system to induce sustained cancer regression.Behavioral and clinical factors associated with self-reported abnormal Papanicolaou tests in rheumatoid arthritisAn essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute StudyImmunologic Control of Mus musculus Papillomavirus Type 1.The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection.Chlamydia trachomatis and risk of cervical intraepithelial neoplasia grade 3 or worse in women with persistent human papillomavirus infection: a cohort study.Cervical HPV prevalence and genotype distribution in immunosuppressed Danish women.HIV-positive women have higher risk of HPV infection, precancerous lesions, and cervical cancer: a systematic review and meta-analysis.Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization.Risks of female genital tract related cancers (gynecological cancers) or breast cancer in women with and without chronic kidney disease: A population-based cohort study in Taiwan.Assessment and monitoring of biologic drug adverse events in patients with psoriasis.Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: Population-based cohort studyAdvances and Prospects in Cancer Immunotherapy
P2860
Q26774682-96D8A3BA-5809-40B9-8BF5-720001B82DC9Q28086919-C42E0403-32AC-4B4B-9E88-EED156817D35Q33987633-920D9811-A591-4CA2-966D-B5D40CCEAC5DQ34154461-0A27C8DC-BC4D-4CAC-A4EA-46BB77D57FCCQ34361976-FBBA0168-D66B-41A3-87BD-2FE4589AB153Q35818080-81FE6BA3-989C-499D-88FC-3145D0236898Q35818624-DD7F70C3-C914-49AC-B1FF-72987F4B7679Q37614753-13CC548C-8FEF-4C2A-99DA-DEEC1EC4E60CQ37844517-9D718A48-6724-4F89-A405-84F862266617Q47212161-6D86D2D5-4841-47C3-B201-2C515750F7F1Q47548955-D334BFC9-1FED-4852-837D-B7B7A87EA48BQ48107208-402044FB-8CCE-427C-892F-5B69CB221739Q52645239-7AB762D8-4E9E-4CE0-B08A-BA3D2ABBED41Q55153984-1957119E-D247-467F-BC48-742297C6D550Q57593842-16A0F8E9-4FE1-4B60-9F28-09CAB0AC50DFQ59072375-19791430-CABF-4B93-BFC6-699188EE7F5C
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immunosuppression and risk of cervical cancer.
@en
type
label
Immunosuppression and risk of cervical cancer.
@en
prefLabel
Immunosuppression and risk of cervical cancer.
@en
P2860
P50
P356
P1476
Immunosuppression and risk of cervical cancer.
@en
P2093
Matejka Rebolj
Pierre-Antoine Dugué
P2860
P356
10.1586/ERA.12.159
P577
2013-01-01T00:00:00Z